Nateglinide Articles
Japan stock market week to Jan 5, 2009
12 January 2009
Japan stock market week to Nov 26, 2007
3 December 2007
Japan stock market week to Dec 4, 2006
11 December 2006
3% underlying sales rise at Yamanouchi
23 August 2004
Analysts see threat to Novartis' Lotrel
6 January 2003
Starlix boosts metformin efficacy
24 June 2002
Novartis' Starlix aids glucose control
20 May 2002
Tokyo pharma stocks - week to March 4
11 March 2002
Merck KGaA confident of surviving Glucophage declines
25 February 2002
Double-digit turnover growth for Novartis in 2001
11 February 2002
Tokyo pharma stocks to December 31, 2001
7 January 2002
Novartis launches largest diabetes study
13 September 2001
Novartis' Zometa finally wins FDA approval
22 August 2001
Novartis' six-month 2001 net income jumps 10%, sales up 11%
16 August 2001
Major study looks at Novartis drugs in IGT
26 June 2001
Novartis 1st qtr pharma sales rise 13%
19 April 2001
Starlix cleared in EU
5 April 2001
Merck KGaA sets out plan to become number one in core businesses
20 February 2001
Novartis expects five new products to drive growth in 2001
15 February 2001
Novartis looking to get bigger
31 January 2001
Novartis gains FDA OK for Starlix
28 December 2000
Germany's Merck KGaA taking over Molteni Pharma of Italy
11 December 2000
Novartis R&D day updates prospects for key pipeline drugs
7 December 2000
Modernizing Merck KGaA looking to long-term growth from pharma
8 November 2000
Novartis wins Starlix OK in Switzerland
5 October 2000
Merck KGaA looking to expand alliances
4 October 2000
Novartis gets FTC OK to buy Wesley Jessen
4 October 2000
Merck KGaA/Novartis link up for diabetes
8 August 2000
Novartis says 25% chance Zelmac NDA will not be accepted
22 February 2000
Busy year for NCEs as major new compound classes launched
6 January 2000
Novartis seeks US, European Starlix OK
23 December 1999
Stock Commentary Tokyo
16 December 1999
Yamanouchi watching Lipitor developments
24 November 1999
Novartis' nateglinide "corrects metabolic defect"
14 October 1999
Novartis upbeat at biannual R&D update
23 September 1999
Novo Nordisk's Prandin plus Rezulin, insulin
24 June 1999
Novartis to market 21 new drugs by 2002
25 January 1999
Showing 1-63 of 63 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
